

**PRODUCT INFORMATION**

<b>Clone ID</b>	1G9
<b>Target</b>	CL2A
<b>Synonyms</b>	N.A.
<b>Host Species</b>	Rabbit
<b>Description</b>	Anti-CL2A(ADC linker) antibody(1G9); Rabbit mAb
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	N.A.
<b>IgG type</b>	Rabbit IgG
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	N.A.
<b>Applications</b>	ELISA
<b>Recommended Dilutions</b>	ELISA 1:5000-10000
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scr



### ELISA assay to evaluate Anti-CL2A Antibody 0.2 $\mu$ g Human IgG-CL2A per well




Figure1. Elisa plates were pre-coated with IgG-CL2A (0.2 $\mu$ g/per well). Serial diluted anti-CL2A monoclonal antibody (DME101022) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-CL2A monoclonal antibody binding with IgG-CL2A is 12.57ng/ml.

